Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

FORTREA ($FTRE) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of $0.18 per share, missing estimates of $0.37 by $0.19. The ...

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.19 per share a year ago.

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

$FTRE insiders have traded $FTRE stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales. We have seen 115 ...

(RTTNews) - Below are the earnings highlights for Fortrea Holdings Inc. (FTRE): Earnings ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

DURHAM, N.C., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that it will appoint Erin L. Russell, a financial ...

Fortrea, a global contract research organization, has announced the appointment of Erin L. Russell as an independent member of its Board of Directors, effective immediately before the next board ...

Learn more and get involved at Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large ...

DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to ...